Table 3.
Mean costs per patient during observation period (no discounting)
|
Item |
S-1 therapy
|
Surgery alone
|
||
|---|---|---|---|---|
|
Unit cost ($) |
Quantity |
Cost ($) |
Quantity |
Cost ($) |
| (No. of units) | (No. of units) | |||
| Consultation |
|
|
|
|
| Outpatient: 5.8 |
22.4 |
131 |
8.3 |
49 |
| Treatment |
|
|
|
|
| S-1 drug (mg): 0.3 |
15,156 |
4,367 |
NA |
|
| Prescription: 4.9 |
10.5 |
52 |
NA |
|
| Tests |
|
|
|
|
| Imaging tests |
|
|
|
|
| CT: 124.3 |
5.1 |
629 |
4.9 |
608 |
| Chest X-ray: 21.1 |
2.0 |
42 |
2.0 |
43 |
| Echogram: 44.2 |
1.8 |
80 |
1.9 |
85 |
| Endoscopy: 95.0 |
1.5 |
147 |
1.7 |
164 |
| Others: 156.0 |
0.2 |
34 |
0.2 |
38 |
| Laboratory tests |
|
|
|
|
| Blood test: 35.0 |
21.3 |
746 |
9.1 |
319 |
| Tumor markers: 33.3 |
8.6 |
286 |
8.6 |
288 |
| Adverse effects |
|
|
|
|
| Anti-ulcerants: 6.0 |
0.3 |
2 |
0.2 |
1 |
| Anti-biotics: 15.4 |
0.2 |
3 |
0.1 |
1 |
| Anti-diarrhoeals: 5.4 |
0.2 |
1 |
0.1 |
0 |
| Anti-emetics: 64.8 |
0.1 |
9 |
0.0 |
3 |
| G-CSF: 106.9 |
0.0 |
3 |
0.0 |
0 |
| Blood transfusion: 188.5 |
0.0 |
0 |
0.0 |
1 |
| Recurrence |
|
|
|
|
| S-1: 3,694 |
0.1 |
487 |
0.3 |
1,394 |
| Paclitaxel: 5,298 |
0.1 |
422 |
0.0 |
101 |
| S-1 + cisplatin: 5,594 |
0.0 |
227 |
0.1 |
244 |
| S-1 + paclitaxel: 5,247 |
0.0 |
162 |
0.0 |
129 |
| 5FU + methotrexate: 4,748 |
0.0 |
65 |
0.0 |
144 |
| Irinotecan + cisplatin: 5,197 |
0.0 |
162 |
0.0 |
43 |
| Others: 4,892 |
0.0 |
211 |
0.0 |
201 |
| End of life |
|
|
|
|
| Drugs/injections |
0.3 |
1,064 |
0.4 |
1,367 |
| Treatments |
0.3 |
233 |
0.4 |
321 |
| Operations/anesthesia |
0.3 |
213 |
0.4 |
296 |
| Diagnostic tests |
0.3 |
221 |
0.4 |
353 |
| Total costs per patient |
11,103 |
7,761 |
||
| (SD) | (6,832) | (6,787) | ||
NA = not applicable.